CA2903582C - Oncolytic adenovirus compositions - Google Patents
Oncolytic adenovirus compositions Download PDFInfo
- Publication number
- CA2903582C CA2903582C CA2903582A CA2903582A CA2903582C CA 2903582 C CA2903582 C CA 2903582C CA 2903582 A CA2903582 A CA 2903582A CA 2903582 A CA2903582 A CA 2903582A CA 2903582 C CA2903582 C CA 2903582C
- Authority
- CA
- Canada
- Prior art keywords
- adenovirus
- recombinant adenovirus
- e4orf6
- cancer
- deletion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 320
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 230000000174 oncolytic effect Effects 0.000 title description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 222
- 229920001184 polypeptide Polymers 0.000 claims abstract description 219
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 219
- 230000004048 modification Effects 0.000 claims abstract description 142
- 238000012986 modification Methods 0.000 claims abstract description 142
- 230000002062 proliferating effect Effects 0.000 claims abstract description 46
- 210000004027 cell Anatomy 0.000 claims description 205
- 238000012217 deletion Methods 0.000 claims description 117
- 230000037430 deletion Effects 0.000 claims description 117
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 106
- 206010028980 Neoplasm Diseases 0.000 claims description 101
- 108090000623 proteins and genes Proteins 0.000 claims description 92
- 238000006467 substitution reaction Methods 0.000 claims description 58
- 201000011510 cancer Diseases 0.000 claims description 54
- 125000000539 amino acid group Chemical group 0.000 claims description 50
- 150000001413 amino acids Chemical class 0.000 claims description 50
- 208000032839 leukemia Diseases 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 33
- 230000037361 pathway Effects 0.000 claims description 32
- 229940124597 therapeutic agent Drugs 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 230000002950 deficient Effects 0.000 claims description 27
- 108700024394 Exon Proteins 0.000 claims description 25
- 108020004705 Codon Proteins 0.000 claims description 23
- 101150101112 7 gene Proteins 0.000 claims description 21
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims description 19
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims description 19
- 239000002246 antineoplastic agent Substances 0.000 claims description 18
- 206010006187 Breast cancer Diseases 0.000 claims description 15
- 229940127089 cytotoxic agent Drugs 0.000 claims description 15
- 208000026310 Breast neoplasm Diseases 0.000 claims description 13
- 210000004899 c-terminal region Anatomy 0.000 claims description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 12
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 12
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 208000020816 lung neoplasm Diseases 0.000 claims description 12
- 201000002510 thyroid cancer Diseases 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
- 206010038389 Renal cancer Diseases 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 10
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 10
- 108050002653 Retinoblastoma protein Proteins 0.000 claims description 10
- 201000010982 kidney cancer Diseases 0.000 claims description 10
- 201000007270 liver cancer Diseases 0.000 claims description 10
- 208000014018 liver neoplasm Diseases 0.000 claims description 10
- 238000007918 intramuscular administration Methods 0.000 claims description 9
- 238000007912 intraperitoneal administration Methods 0.000 claims description 9
- 238000007920 subcutaneous administration Methods 0.000 claims description 9
- 238000007913 intrathecal administration Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 74
- 150000007523 nucleic acids Chemical class 0.000 description 82
- 241000700605 Viruses Species 0.000 description 79
- 102000039446 nucleic acids Human genes 0.000 description 68
- 108020004707 nucleic acids Proteins 0.000 description 68
- 208000015181 infectious disease Diseases 0.000 description 66
- 102000004169 proteins and genes Human genes 0.000 description 64
- 201000009030 Carcinoma Diseases 0.000 description 61
- 201000010099 disease Diseases 0.000 description 54
- 235000018102 proteins Nutrition 0.000 description 54
- 235000001014 amino acid Nutrition 0.000 description 48
- 229940024606 amino acid Drugs 0.000 description 46
- 230000035772 mutation Effects 0.000 description 45
- 208000035475 disorder Diseases 0.000 description 43
- 239000013598 vector Substances 0.000 description 32
- 239000000047 product Substances 0.000 description 26
- 230000010076 replication Effects 0.000 description 25
- 206010039491 Sarcoma Diseases 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 20
- 102400001301 Gasdermin-B, C-terminal Human genes 0.000 description 20
- 230000001413 cellular effect Effects 0.000 description 20
- 230000007547 defect Effects 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- 230000003612 virological effect Effects 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 230000001771 impaired effect Effects 0.000 description 15
- 235000002639 sodium chloride Nutrition 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 230000003833 cell viability Effects 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 230000004543 DNA replication Effects 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- 230000006870 function Effects 0.000 description 12
- 230000002147 killing effect Effects 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000029812 viral genome replication Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 208000005017 glioblastoma Diseases 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000003119 immunoblot Methods 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 108050006400 Cyclin Proteins 0.000 description 9
- 102000016736 Cyclin Human genes 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 230000003211 malignant effect Effects 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000013207 serial dilution Methods 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 230000018199 S phase Effects 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 206010061289 metastatic neoplasm Diseases 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 108091005461 Nucleic proteins Proteins 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000001394 metastastic effect Effects 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 6
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 101710172711 Structural protein Proteins 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 210000001552 airway epithelial cell Anatomy 0.000 description 6
- 230000022534 cell killing Effects 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 201000005249 lung adenocarcinoma Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 101100161875 Arabidopsis thaliana ACR2 gene Proteins 0.000 description 5
- 101100495264 Arabidopsis thaliana CDC25 gene Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 101100380266 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ARR2 gene Proteins 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 101150004068 acrB gene Proteins 0.000 description 5
- 210000001130 astrocyte Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- -1 hydrochloric Chemical class 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 244000309459 oncolytic virus Species 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 208000011581 secondary neoplasm Diseases 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 208000006332 Choriocarcinoma Diseases 0.000 description 4
- 101150066038 E4 gene Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010029260 Neuroblastoma Diseases 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100039120 Retinoblastoma-like protein 1 Human genes 0.000 description 4
- 108050002592 Retinoblastoma-like protein 1 Proteins 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000003747 lymphoid leukemia Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229930182817 methionine Chemical group 0.000 description 4
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 4
- 208000025113 myeloid leukemia Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 208000009458 Carcinoma in Situ Diseases 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102000002554 Cyclin A Human genes 0.000 description 3
- 108010068192 Cyclin A Proteins 0.000 description 3
- 102000002427 Cyclin B Human genes 0.000 description 3
- 108010068150 Cyclin B Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010093502 E2F Transcription Factors Proteins 0.000 description 3
- 102000001388 E2F Transcription Factors Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 241000598171 Human adenovirus sp. Species 0.000 description 3
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 3
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 description 3
- 102100022828 Retinoblastoma-like protein 2 Human genes 0.000 description 3
- 108050002651 Retinoblastoma-like protein 2 Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 208000035269 cancer or benign tumor Diseases 0.000 description 3
- 230000012820 cell cycle checkpoint Effects 0.000 description 3
- 238000003570 cell viability assay Methods 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 201000006894 monocytic leukemia Diseases 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 201000005987 myeloid sarcoma Diseases 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000002437 synoviocyte Anatomy 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 108010018673 Adenovirus Early Proteins Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 2
- 108091007914 CDKs Proteins 0.000 description 2
- 206010008583 Chloroma Diseases 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010053574 Immunoblastic lymphoma Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 description 2
- 206010050017 Lung cancer metastatic Diseases 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 201000001542 Schneiderian carcinoma Diseases 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 2
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 2
- 108700019030 adenovirus E4orf6 Proteins 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003263 anti-adenoviral effect Effects 0.000 description 2
- 230000000719 anti-leukaemic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000002074 deregulated effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 201000004933 in situ carcinoma Diseases 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 208000025036 lymphosarcoma Diseases 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000002418 meninge Anatomy 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 208000031223 plasma cell leukemia Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- OOVTUOCTLAERQD-OJMBIDBESA-N 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one;hydrochloride Chemical compound Cl.OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O OOVTUOCTLAERQD-OJMBIDBESA-N 0.000 description 1
- MRPGRAKIAJJGMM-OCCSQVGLSA-N 2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one Chemical compound OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC(=CC=1)C(F)(F)F)Cl)=CC2=O MRPGRAKIAJJGMM-OCCSQVGLSA-N 0.000 description 1
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- WJRRGYBTGDJBFX-UHFFFAOYSA-N 4-(2-methyl-3-propan-2-yl-4-imidazolyl)-N-(4-methylsulfonylphenyl)-2-pyrimidinamine Chemical compound CC(C)N1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=N1 WJRRGYBTGDJBFX-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000035805 Aleukaemic leukaemia Diseases 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100165660 Alternaria brassicicola bsc6 gene Proteins 0.000 description 1
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 101100172201 Arabidopsis thaliana ELP2 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101710082924 Atypical protein kinase C Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 101100499295 Bacillus subtilis (strain 168) disA gene Proteins 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101100064559 Drosophila melanogaster E2f1 gene Proteins 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010057649 Endometrial sarcoma Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 208000002519 Epithelioid Leiomyoma Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 208000009331 Experimental Sarcoma Diseases 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102220502351 Golgin subfamily A member 1_L5A_mutation Human genes 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 208000017662 Hodgkin disease lymphocyte depletion type stage unspecified Diseases 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 210000005131 Hürthle cell Anatomy 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102220478991 Interleukin-4 receptor subunit alpha_P117A_mutation Human genes 0.000 description 1
- 206010023256 Juvenile melanoma benign Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical group C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Chemical group CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010024218 Lentigo maligna Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010053180 Leukaemia cutis Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102220496360 MAGUK p55 subfamily member 3_D68A_mutation Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 101150007210 ORF6 gene Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 101100226894 Phomopsis amygdali PaGT gene Proteins 0.000 description 1
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101100278874 Prunus persica GNS1 gene Proteins 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 101150076031 RAS1 gene Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102220552706 Replication protein A 14 kDa subunit_L86A_mutation Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000000341 S-Phase Kinase-Associated Proteins Human genes 0.000 description 1
- 108010055623 S-Phase Kinase-Associated Proteins Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 101100501248 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ELO2 gene Proteins 0.000 description 1
- 101000744436 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Trans-acting factor D Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 101100273887 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) cedB gene Proteins 0.000 description 1
- 101100234062 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) cmk gene Proteins 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102220470387 Thymosin beta-10_Y26A_mutation Human genes 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000012018 Yolk sac tumor Diseases 0.000 description 1
- 102220515303 Zinc finger protein 395_L109A_mutation Human genes 0.000 description 1
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 208000008524 alveolar soft part sarcoma Diseases 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- 208000006431 amelanotic melanoma Diseases 0.000 description 1
- 230000002707 ameloblastic effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000016894 basaloid carcinoma Diseases 0.000 description 1
- 201000000450 basaloid squamous cell carcinoma Diseases 0.000 description 1
- 208000003373 basosquamous carcinoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000010983 breast ductal carcinoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000011050 comedo carcinoma Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 201000011063 cribriform carcinoma Diseases 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 208000001991 endodermal sinus tumor Diseases 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 208000017750 granulocytic sarcoma Diseases 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- SETFNECMODOHTO-UHFFFAOYSA-N indisulam Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 description 1
- 229950009881 indisulam Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 208000011080 lentigo maligna melanoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000610 leukopenic effect Effects 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 201000000966 lung oat cell carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 201000010953 lymphoepithelioma-like carcinoma Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000012966 malignant exocrine pancreas neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000000684 melanotic effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000001466 metabolic labeling Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037843 metastatic solid tumor Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 208000029809 non-keratinizing sinonasal squamous cell carcinoma Diseases 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 230000008481 normal tissue growth Effects 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 208000029817 pulmonary adenocarcinoma in situ Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 102200039498 rs12037217 Human genes 0.000 description 1
- 102220322140 rs1554840836 Human genes 0.000 description 1
- 102200052245 rs199469625 Human genes 0.000 description 1
- 102200022340 rs200412910 Human genes 0.000 description 1
- 102220188353 rs886057420 Human genes 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 208000004259 scirrhous adenocarcinoma Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 208000011584 spitz nevus Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 208000028210 stromal sarcoma Diseases 0.000 description 1
- 201000010033 subleukemic leukemia Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000990167 unclassified Simian adenoviruses Species 0.000 description 1
- 208000022810 undifferentiated (embryonal) sarcoma Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 208000008662 verrucous carcinoma Diseases 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000008299 viral mechanism Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3115891A CA3115891A1 (en) | 2013-03-14 | 2014-03-14 | Oncolytic adenovirus compositions |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782932P | 2013-03-14 | 2013-03-14 | |
| US61/782,932 | 2013-03-14 | ||
| PCT/US2014/029587 WO2014153204A1 (en) | 2013-03-14 | 2014-03-14 | Oncolytic adenovirus compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3115891A Division CA3115891A1 (en) | 2013-03-14 | 2014-03-14 | Oncolytic adenovirus compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2903582A1 CA2903582A1 (en) | 2014-09-25 |
| CA2903582C true CA2903582C (en) | 2021-06-08 |
Family
ID=51581449
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2903582A Active CA2903582C (en) | 2013-03-14 | 2014-03-14 | Oncolytic adenovirus compositions |
| CA3115891A Abandoned CA3115891A1 (en) | 2013-03-14 | 2014-03-14 | Oncolytic adenovirus compositions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3115891A Abandoned CA3115891A1 (en) | 2013-03-14 | 2014-03-14 | Oncolytic adenovirus compositions |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11077156B2 (enExample) |
| EP (1) | EP2971008B1 (enExample) |
| JP (1) | JP6576326B2 (enExample) |
| KR (1) | KR102089121B1 (enExample) |
| AU (1) | AU2014236207B2 (enExample) |
| CA (2) | CA2903582C (enExample) |
| SG (1) | SG11201507393TA (enExample) |
| WO (1) | WO2014153204A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| US10947500B2 (en) * | 2014-06-27 | 2021-03-16 | Angiocrine Bioscience, Inc. | Neural cells expressing adenovirus E4ORF1, and methods of making and using the same |
| DK3198009T3 (da) * | 2014-09-24 | 2021-11-22 | Salk Inst For Biological Studi | Onkolytiske tumorvira og anvendelsesfremgangsmåder |
| ES2837400T3 (es) | 2015-10-05 | 2021-06-30 | Salk Inst For Biological Studi | Adenovirus sintético con tropismo para los tejidos dañados para su uso en la promoción de la reparación de heridas y regeneración tisular |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CA3060573A1 (en) | 2017-04-21 | 2018-10-25 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| WO2018204677A1 (en) * | 2017-05-04 | 2018-11-08 | Epicentrx, Inc. | Oncolytic adenovirus formulation |
| CA3092907A1 (en) * | 2018-03-05 | 2019-09-12 | Klinikum Rechts Der Isar Der Technischen Universitat Munchen | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| WO2019202118A1 (en) * | 2018-04-20 | 2019-10-24 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| US12329793B2 (en) | 2019-03-20 | 2025-06-17 | National University Corporation Hokkaido University | Modified adenovirus and medicine comprising same |
| US20220354911A1 (en) * | 2019-09-05 | 2022-11-10 | Klinikum Rechts Der Isar Der Technischen Universität München | Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent |
| US20230071166A1 (en) * | 2021-08-12 | 2023-03-09 | The University Of Chicago | One-step method for producing adenoviral vectors |
Family Cites Families (329)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| PT931830E (pt) | 1993-02-16 | 2001-08-30 | Onyx Pharma Inc | Virus citopaticos para terapia e profilaxia de neoplasia |
| US7045347B2 (en) | 1993-06-24 | 2006-05-16 | Advec, Inc. | Helper dependent adenovirus vectors based on integrase family site-specific recombinases |
| US20010006629A1 (en) | 1993-10-25 | 2001-07-05 | Richard J. Gregory | Recombinant adenoviral vector and methods of use |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5962311A (en) | 1994-09-08 | 1999-10-05 | Genvec, Inc. | Short-shafted adenoviral fiber and its use |
| US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| FR2726285B1 (fr) | 1994-10-28 | 1996-11-29 | Centre Nat Rech Scient | Adenovirus depourvus de particules contaminantes viables, preparation et utilisation |
| CA2206683A1 (en) | 1994-12-12 | 1996-06-20 | Genetic Therapy, Inc. | Improved adenoviral vectors and producer cells |
| US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| US20030026789A1 (en) | 1995-05-03 | 2003-02-06 | Richard J. Gregory | Gene therapy using replication competent targeted adenoviral vectors |
| US6506379B1 (en) | 1995-06-07 | 2003-01-14 | Ariad Gene Therapeutics, Inc. | Intramuscular delivery of recombinant AAV |
| AUPN477695A0 (en) | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
| US5945335A (en) * | 1995-11-09 | 1999-08-31 | Avigen, Inc. | Adenovirus helper-free system for producing recombinant AAV virions lacking oncogenic sequences |
| US6083720A (en) | 1995-11-13 | 2000-07-04 | Chroboczek; Jadwiga | Dodecahedral adenoviral protein complex, composition containing same and uses thereof |
| IL124654A0 (en) | 1995-11-28 | 1998-12-06 | Genvec Inc | Vectors and method for gene transfer to cells |
| US6133243A (en) | 1996-02-22 | 2000-10-17 | Onyx Pharmaceuticals, Inc. | Liposomal-viral DNA complexes for treating disease |
| FR2746110B1 (fr) | 1996-03-14 | 1998-04-17 | Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants | |
| US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| IL127692A0 (en) | 1996-07-01 | 1999-10-28 | Rhone Poulenc Rorer Sa | Method for producing recombinant adenovirus |
| US7232899B2 (en) | 1996-09-25 | 2007-06-19 | The Scripps Research Institute | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
| US5922315A (en) | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
| US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
| US20050287120A1 (en) | 1997-03-21 | 2005-12-29 | Fisher Paul B | Cancer - targeted viral vectors |
| FR2761689B1 (fr) | 1997-04-02 | 1999-06-25 | Transgene Sa | Fibre adenovirale modifiee et adenovirus cibles |
| CA2291323A1 (en) | 1997-05-28 | 1998-12-03 | Genvec, Inc. | Alternatively targeted adenovirus |
| US6200799B1 (en) * | 1997-06-03 | 2001-03-13 | University Of Lausanne | Somatic gene therapy to suppress secondary cataract formation following eye surgery |
| AU8067698A (en) | 1997-06-09 | 1998-12-30 | Genvec, Inc. | Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus |
| CN1281512A (zh) | 1997-12-12 | 2001-01-24 | 昂尼克斯药物公司 | p53+肿瘤细胞的选择性杀伤和诊断 |
| CN1304316A (zh) | 1998-02-06 | 2001-07-18 | 亚拉巴马大学伯明翰分校研究基金会 | 在纤维结的hi环中含有异源肽表位的腺病毒载体 |
| US6984635B1 (en) | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
| AU751542B2 (en) | 1998-02-17 | 2002-08-22 | Uab Research Foundation, The | Modified adenovirus containing a fiber replacement protein |
| US20050095231A1 (en) | 1998-02-17 | 2005-05-05 | Curiel David T. | Modified adenovirus containing a fiber replacement protein |
| AU2796799A (en) | 1998-03-03 | 1999-09-20 | Uab Research Foundation, The | Amplification of gene transfer and gene therapy by controlled replication |
| AU3358999A (en) | 1998-03-20 | 1999-10-11 | Genzyme Corporation | Chimeric adenoviral vectors for targeted gene delivery |
| US6670188B1 (en) | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US7829329B2 (en) | 1998-04-24 | 2010-11-09 | Onyx Pharmaceuticals, Inc. | Adenoviral vectors for treating disease |
| DK1199368T3 (da) | 1998-07-07 | 2004-04-13 | Transgene Sa | Anvendelse af adenovirus-E4-læserammer til forbedring af ekspression af et gen af interesse |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| WO2000012738A1 (en) | 1998-08-27 | 2000-03-09 | Aventis Pharma S.A. | Targeted adenovirus vectors for delivery of heterologous genes |
| US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| CA2342396A1 (en) | 1998-09-11 | 2000-03-23 | Genvec, Inc. | Alternatively targeted adenovirus |
| US6841540B1 (en) | 1998-09-29 | 2005-01-11 | The Uab Research Foundation | Immunomodulation by genetic modification of dendritic cells and B cells |
| PL347898A1 (en) | 1998-10-15 | 2002-04-22 | Canji | Selectively replicating viral vectors |
| US20020037274A1 (en) | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
| US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| CA2359795A1 (en) | 1999-01-14 | 2000-07-20 | Novartis Ag | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
| US7157266B2 (en) | 1999-01-25 | 2007-01-02 | Brookhaven Science Associates Llc | Structure of adenovirus bound to cellular receptor car |
| US6395875B1 (en) | 1999-01-25 | 2002-05-28 | Brookhaven Science Associates Llc | Recombinant soluble adenovirus receptor |
| JP4683727B2 (ja) | 1999-03-04 | 2011-05-18 | クルーセル ホランド ベスローテン フェンノートシャップ | 線維芽細胞様またはマクロファージ様細胞の形質導入のための手段と方法 |
| US6869936B1 (en) | 1999-03-04 | 2005-03-22 | Crucell Holland B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
| AU767904B2 (en) | 1999-05-12 | 2003-11-27 | Uab Research Foundation, The | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| US20040175362A1 (en) | 1999-05-12 | 2004-09-09 | Curiel David T. | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| EP1816204B1 (en) | 1999-05-17 | 2010-10-20 | Crucell Holland B.V. | Recombinant Adenovirus of the Ad26 serotype |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US20050232900A1 (en) | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| EP1593742A3 (en) | 1999-06-01 | 2006-02-01 | The University of Washington | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection |
| US7094398B1 (en) | 1999-06-01 | 2006-08-22 | University Of Washington | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| EP1181382B1 (en) | 1999-06-01 | 2005-03-23 | The University of Washington | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| DE19929569A1 (de) | 1999-06-21 | 2000-12-28 | Holm Per Sonne | Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1 |
| JP2003531568A (ja) | 1999-07-06 | 2003-10-28 | ゴット−エー−ジェーン・エービー | 組換え型アデノウイルス |
| US7589069B1 (en) | 1999-07-12 | 2009-09-15 | Saint Louis University | Replication-competent anti-cancer vectors |
| WO2001016344A1 (fr) | 1999-08-27 | 2001-03-08 | Transgene S.A. | Fibre adenovirale modifiee et utilisations |
| AU1070901A (en) | 1999-09-23 | 2001-04-24 | Genvec, Inc. | Method of treating cells of the prostate prophylactically or therapeutically |
| CA2384827A1 (en) | 1999-09-24 | 2001-03-29 | The Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
| AU1190901A (en) | 1999-09-30 | 2001-04-30 | Trustees Of The University Of Pennsylvania, The | Replication selective adenoviruses for use in cancer therapy |
| US6635476B1 (en) | 1999-10-15 | 2003-10-21 | Canji, Inc. | Targeted vectors |
| MXPA02004736A (es) | 1999-11-12 | 2003-01-28 | Oncolytics Biotech Inc | Virus para el tratamiento de trastornos proliferativos celulares. |
| US7001596B1 (en) | 1999-11-15 | 2006-02-21 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| US6867022B1 (en) | 2000-01-21 | 2005-03-15 | Regents Of The University Of Michigan | Replication deficient adenovirus vectors and methods of making and using them |
| AU2001234981A1 (en) | 2000-02-09 | 2001-08-20 | Genvec, Inc. | Adenoviral capsid containing chimeric protein ix |
| US6911200B2 (en) | 2000-03-24 | 2005-06-28 | Cell Genesys, Inc. | Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation |
| DE60136268D1 (de) | 2000-03-24 | 2008-12-04 | Cell Genesys Inc | Interne ribosomenzugangsstelle-enthaltende zell-spezifische adenovirale vektoren |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| US20030082146A1 (en) | 2000-04-26 | 2003-05-01 | Van Es Helmuth H. G. | Adenovirus vectors with knobless fibers, and their uses |
| EP1280929A2 (en) | 2000-05-01 | 2003-02-05 | Novartis AG | Vectors for ocular transduction and use thereof for genetic therapy |
| US7332337B2 (en) | 2000-05-16 | 2008-02-19 | Galapagos Nv | Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells |
| EP1157999A1 (en) | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
| EP1284294A4 (en) | 2000-05-26 | 2004-10-13 | Sumitomo Pharma | RECOMBINANT ADENOVIRUS WITH REDUCED SIDE EFFECTS (12/05/01) |
| EP1301612A2 (en) | 2000-05-31 | 2003-04-16 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| AU6368901A (en) | 2000-05-31 | 2001-12-11 | Univ Saskatchewan | Modified bovine adenovirus having altered tropism |
| US7754201B2 (en) | 2000-06-02 | 2010-07-13 | GenPhar, Inc | Method of vaccination through serotype rotation |
| EP1167533A1 (en) | 2000-06-23 | 2002-01-02 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Methods and means for the complementation of viral protein expression in stable cell lines |
| US6579522B1 (en) | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
| US7022496B2 (en) | 2000-07-14 | 2006-04-04 | The Johns Hopkins University | Use of gene product of adenovirus early region 4 ORF-6 to inhibit repair of double-strand breaks in DNA |
| US20020106382A1 (en) | 2000-07-14 | 2002-08-08 | Young Charles S.H. | Modified adenovirus and uses thereof |
| GB0017720D0 (en) | 2000-07-19 | 2000-09-06 | Got A Gene Ab | Modified virus |
| WO2002012523A2 (en) | 2000-08-10 | 2002-02-14 | Crucell Holland B.V. | Transduction of chondrocytes using adenoviral vectors |
| US7235233B2 (en) | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
| WO2002046372A1 (en) | 2000-12-08 | 2002-06-13 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
| US20030095989A1 (en) | 2000-12-18 | 2003-05-22 | Irving John M. | Chimeric cytolytic viruses for cancer treatment |
| US6635466B2 (en) | 2001-01-09 | 2003-10-21 | University Of Iowa Research Foundation | Adenovirus serotype 30 (Ad30) |
| WO2002064746A2 (en) | 2001-02-14 | 2002-08-22 | Uab Research Foundation | Combined transductional and transcriptional targeting system for improved gene delivery |
| IL152420A0 (en) | 2001-02-23 | 2003-05-29 | Novartis Ag | Novel oncolytic adenoviral vectors |
| JP2005525779A (ja) | 2001-04-02 | 2005-09-02 | バイエル アクチェンゲゼルシャフト | 核酸構築物のトランスフェクションによって、身体サンプルから細胞を特異的に検出、単離および特徴付けするための方法 |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| US20030219899A1 (en) | 2001-04-17 | 2003-11-27 | Nikolay Korokhov | Mosaic adenoviral vectors |
| US20020151069A1 (en) | 2001-04-17 | 2002-10-17 | Nikolay Korokhov | Mosaic adenoviral vectors |
| ES2375557T3 (es) | 2001-06-22 | 2012-03-02 | The Trustees Of The University Of Pennsylvania | Adenovirus recombinantes que comprenden prote�?nas de adenovirus de simios y usos de los mismos. |
| US6844192B2 (en) * | 2001-06-29 | 2005-01-18 | Wake Forest University | Adenovirus E4 protein variants for virus production |
| US6905678B2 (en) | 2001-07-07 | 2005-06-14 | Crucell Holland B.V. | Gene delivery vectors with cell type specificity for mesenchymal stem cells |
| JP2004536607A (ja) | 2001-07-23 | 2004-12-09 | オニックス ファーマシューティカルズ，インコーポレイティド | 標的化されたヒト癌細胞において選択的に複製するウイルス変異体 |
| CA2460157A1 (en) | 2001-09-18 | 2003-03-27 | Clontech Laboratories, Inc. | Site-specific recombinase based method for producing adenoviral vectors |
| US7569217B2 (en) * | 2001-09-24 | 2009-08-04 | University Of Saskatchewan | Porcine adenovirus E1 and E4 regions |
| AU2002343901A1 (en) | 2001-09-29 | 2003-04-14 | Kim, Joo-Hang | Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus |
| KR100987360B1 (ko) | 2001-11-21 | 2010-10-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법 |
| CN100475966C (zh) | 2001-11-23 | 2009-04-08 | 上海三维生物技术有限公司 | 具有肿瘤细胞特异性感染和转基因表达能力的新型腺病毒 |
| EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| WO2003062400A2 (en) | 2002-01-24 | 2003-07-31 | The Scripps Research Institute | Fiber shaft modifications for efficient targeting |
| AU2003206815A2 (en) | 2002-02-01 | 2003-09-02 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with PODs |
| US20030220284A1 (en) | 2002-02-22 | 2003-11-27 | Patricia Yotnda | Delivery of adenoviral DNA in a liposomal formulation for treatment of disease |
| US20040005710A1 (en) | 2002-03-09 | 2004-01-08 | Ho-Sun Son | Method for producing recombinant viruses using site-specific recombination |
| US7344711B2 (en) | 2002-03-26 | 2008-03-18 | Oncolytics Biotech Inc. | Use of adenoviruses mutated in the VA genes for cancer treatment |
| ES2335657T3 (es) * | 2002-04-25 | 2010-03-31 | Crucell Holland B.V. | Medios y metodos para la produccion de vectores de adenovirus. |
| WO2003092579A2 (en) | 2002-04-29 | 2003-11-13 | Hadasit Medical Research Services And Development Company Ltd. | Compositions and methods for treating cancer with an oncolytic viral agent |
| US7094399B2 (en) | 2002-05-08 | 2006-08-22 | Intronn, Inc. | Use of spliceosome mediated RNA trans-splicing to confer cell selective replication to adenoviruses |
| CN1655827B (zh) | 2002-05-27 | 2010-06-23 | 佩尔·松内·霍尔姆 | 腺病毒和编码其的核酸的新应用 |
| CA2491805A1 (en) | 2002-07-10 | 2004-01-22 | Transgene S.A. | Modified adenoviral fiber with ablated binding to cellular receptors |
| WO2004009768A2 (en) | 2002-07-18 | 2004-01-29 | Invitrogen Corporation | Viral vectors containing recombination sites |
| US7364727B2 (en) | 2002-07-22 | 2008-04-29 | Cell Genesys, Inc. | Metastatic colon cancer specific promoter and uses thereof |
| EP1539937A4 (en) * | 2002-08-22 | 2006-07-26 | Merck & Co Inc | METHOD FOR THE REPRODUCTION OF ADENOVIRUS AND PRODUCT VIRUS THEREWITH |
| US20060099709A1 (en) | 2002-10-01 | 2006-05-11 | Chuan-Yuan Li | Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors |
| EP1413586A1 (en) | 2002-10-21 | 2004-04-28 | Centre National De La Recherche Scientifique (Cnrs) | Regulation of the Cre recombinase using a dissociation/re-association system of said recombinase |
| US20040102382A1 (en) | 2002-11-27 | 2004-05-27 | Transgene, S.A. | Targeting peptides |
| WO2004083418A1 (en) | 2003-03-17 | 2004-09-30 | Merck & Co., Inc. | Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby |
| US20040191761A1 (en) | 2003-03-27 | 2004-09-30 | Routes John M. | Modified adenoviral E1A constructs and methods of use thereof |
| US20040213764A1 (en) | 2003-03-28 | 2004-10-28 | William Wold | Adenovirus replication-competent vectors expressing trail |
| WO2004099422A2 (en) | 2003-03-28 | 2004-11-18 | The Scripps Research Institute | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
| US20040191222A1 (en) | 2003-03-28 | 2004-09-30 | Emini Emilio A. | Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby |
| US20050095705A1 (en) | 2003-04-15 | 2005-05-05 | Michael Kadan | Method for production of oncolytic adenoviruses |
| WO2005027711A2 (en) | 2003-05-01 | 2005-03-31 | University Of Washington | Capsid-modified adenovirus vectors and methods of using the same |
| US7611868B2 (en) | 2003-05-14 | 2009-11-03 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Recombinant modified adenovirus fiber protein |
| US20050079158A1 (en) | 2003-06-05 | 2005-04-14 | Shenzhen Allucks Biotech Co., Ltd. | Construct of anti-cancer recombinant adenovirus, method for preparing the same and use thereof |
| WO2004108755A2 (en) | 2003-06-10 | 2004-12-16 | University Of Saskatchewan | Chimeric adenovirus capsid proteins |
| JP2007531507A (ja) | 2003-06-11 | 2007-11-08 | ザ スクリップス リサーチ インスティテュート | 効率的な受容体結合のための修飾型線維タンパク質 |
| US7291498B2 (en) | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
| US7491508B2 (en) | 2003-06-20 | 2009-02-17 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
| CA2527369A1 (en) | 2003-07-18 | 2005-02-03 | Onyx Pharmaceuticals, Inc. | Subgroup b adenoviral vectors for treating disease |
| ES2391975T3 (es) | 2003-07-25 | 2012-12-03 | Genvec, Inc. | Vacunas a base de vector adenovírico |
| US20050186178A1 (en) | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| AU2003265873A1 (en) | 2003-08-28 | 2005-04-14 | Cell Genesys, Inc. | Oncolytic adenoviral vectors encoding gm-csf |
| WO2005023848A2 (en) | 2003-09-09 | 2005-03-17 | Gardner, Rebecca, Katherine | Adenoviral epitopes |
| US7482156B2 (en) | 2003-10-15 | 2009-01-27 | Cell Genesys, Inc. | Hepatocellular carcinoma specific promoter and uses thereof |
| WO2005051430A1 (de) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierenden nukleinsäuren |
| WO2005048950A2 (en) | 2003-11-17 | 2005-06-02 | Biomune, Inc. | Tumor and infectious disease therapeutic compositions |
| ATE546531T1 (de) | 2003-12-31 | 2012-03-15 | Kalobios Inc | Transaktivierungssystem für säugerzellen |
| WO2005075506A1 (en) | 2004-01-09 | 2005-08-18 | The Scripps Research Institute | Identification of endogenous trimerization domains in the adenovirus fiber protein that allow detargeting and retargeting of viral vectors |
| ES2871907T3 (es) | 2004-01-23 | 2021-11-02 | Msd Italia Srl | Portadores de vacuna de adenovirus de chimpancé |
| US20050201936A1 (en) | 2004-02-12 | 2005-09-15 | Wold William S.M. | Models for viral-based cancer therapy |
| WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| EP1729817B1 (en) | 2004-03-30 | 2014-03-05 | Industry-Academic Cooperation Foundation | Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin |
| WO2005107474A2 (en) | 2004-04-30 | 2005-11-17 | Introgen Therapeutics, Inc. | Oncolytic adenovirus armed with therapeutic genes |
| WO2005106046A1 (en) | 2004-05-03 | 2005-11-10 | Stefan Kochanek | Modified viral vector particles |
| GB0411428D0 (en) | 2004-05-21 | 2004-06-23 | Got A Gene Ab | Vectors |
| WO2005118825A2 (en) | 2004-05-26 | 2005-12-15 | Schering Aktiengesellschaft | Chimeric adenoviruses for use in cancer treatment |
| US20050271622A1 (en) | 2004-06-03 | 2005-12-08 | Shenzhen Allucks Biotech Co., Ltd. | Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof |
| WO2005117993A2 (en) | 2004-06-04 | 2005-12-15 | Genvec, Inc. | Method of using adenoviral vectors with improved safety and efficacy for the treatment of cancer |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| US20060292682A1 (en) | 2004-07-22 | 2006-12-28 | Hawkins Lynda K | Addition of transgenes into adenoviral vectors |
| GB0416487D0 (en) | 2004-07-23 | 2004-08-25 | Isis Innovation | Modified virus |
| US7776322B2 (en) | 2004-08-16 | 2010-08-17 | Stefan Kochanek | Modified viral vector particles |
| WO2006039045A2 (en) | 2004-09-01 | 2006-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
| US7943373B2 (en) | 2004-09-29 | 2011-05-17 | Oncolys Biopharma, Inc. | Telomelysin/GFP-expressing recombinant virus |
| US7741099B2 (en) | 2004-10-13 | 2010-06-22 | Beth Israel Deaconess Medical Center Inc. | Adenoviral vectors and uses thereof |
| MX2007004968A (es) | 2004-10-25 | 2007-06-15 | Novartis Ag | Polinucleotidos y polipeptidos torc, y metodos de uso. |
| IL166049A0 (en) | 2004-12-30 | 2006-01-15 | Gavish Galilee Bio Appl Ltd | Method for obtaining modified proteins and viruseswith intact native binding |
| EP1830864A2 (de) | 2004-12-31 | 2007-09-12 | Per Sonne Holm | E1 -minus adenoviren und deren verwendung |
| AU2006203736B2 (en) | 2004-12-31 | 2012-03-29 | Per Sonne Holm | Method for reversing multiple resistance in animal cells |
| WO2006086357A2 (en) | 2005-02-10 | 2006-08-17 | Merck & Co., Inc. | Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby |
| JP2008538894A (ja) | 2005-02-11 | 2008-11-13 | メルク エンド カムパニー インコーポレーテッド | アデノウイルス血清型２６ベクター、核酸およびそれにより製造されたウイルス |
| KR100747646B1 (ko) | 2005-02-25 | 2007-08-08 | 연세대학교 산학협력단 | 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물 |
| WO2006119449A2 (en) | 2005-05-04 | 2006-11-09 | Vectorlogics, Inc. | Modified adenovirus containing a stabilized antibody |
| WO2007050128A2 (en) | 2005-05-31 | 2007-05-03 | Vectorlogics, Inc. | Shielded adenoviral vectors and methods of use |
| EP1893636A2 (en) | 2005-06-17 | 2008-03-05 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Hepatitis c virus nucleic acid vaccine |
| WO2007027860A2 (en) | 2005-08-31 | 2007-03-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| KR100723009B1 (ko) | 2005-11-30 | 2007-05-29 | 한국원자력연구원 | 인간 ｐ３１ 유전자를 함유하는 악성 종양 치료용 약학적조성물 |
| ES2304281B1 (es) | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| WO2007094653A1 (en) | 2006-02-13 | 2007-08-23 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles. |
| US20070292396A1 (en) | 2006-03-02 | 2007-12-20 | Juan Fueyo | Combination therapy with oncolytic adenovirus |
| US20070292954A1 (en) | 2006-04-21 | 2007-12-20 | The Brigham And Women's Hospital, Inc. | Generation of recombinant DNA by sequence-and ligation-independent cloning |
| US20090074810A1 (en) | 2006-04-28 | 2009-03-19 | The Trustees Of The University Of Pennsylvania | Modified Adenovirus Hexon Protein and Uses Thereof |
| US20080242608A1 (en) | 2006-06-02 | 2008-10-02 | Azad Bonni | Methods and compositions for treating and preventing neurologic disorders |
| EP2041291A1 (en) | 2006-06-19 | 2009-04-01 | Institut Gustave Roussy | Inhibition of the liver tropism of adenoviral vectors |
| JP2008048621A (ja) | 2006-08-22 | 2008-03-06 | Chiba Prefecture | キメラ型アデノウイルスとその作製方法並びにそれを用いた医薬 |
| GR20060100496A (el) | 2006-09-01 | 2008-04-15 | Παρθενιος Μπουλικας | ΛΙΠΟΣΩΜΑΤΙΚΑ ΕΓΚΑΨΥΛΙΩΜΕΝΟΙ ΦΟΡΕΙΣ-ΥΒΡΙΔΙΟΥ ΑΔΕΝΟΙΟΥ - ΙΟΥ SEMLIKI FOREST (SFV), ΠΟΥ ΦΕΡΕΙ ΚΑΤΑΣΚΕΥΑΣΜΑΤΑ RNAi ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΑ ΓΟΝΙΔΙΑ ΠΟΥ ΧΡΗΣΙΜΟΠΟΙΟΥΝΤΑΙ ΕΝΑΝΤΙΟΝ ΣΤΟΧΩΝ ΚΑΡΚΙΝΟΥ ΚΑΙ ΑΛΛΩΝ ΑΣΘΕΝΕΙΩΝ |
| US20100098668A1 (en) | 2006-09-29 | 2010-04-22 | Northshore University Health System | Oncolytic Adenoviruses and Uses Thereof |
| WO2008140474A1 (en) | 2006-10-26 | 2008-11-20 | Johns Hopkins University | Recombinant adenovirus vaccines |
| WO2008065054A1 (en) | 2006-11-28 | 2008-06-05 | Nerviano Medical Sciences S.R.L. | Tricyclic indoles and (4,5-dihydro) indoles |
| WO2008095168A2 (en) | 2007-02-01 | 2008-08-07 | University Of Chicago | Compositions and methods related to a recombinant adenoviral vector that targets il 13 receptors |
| CN101702918B (zh) | 2007-03-14 | 2013-03-27 | 卡塔拉肿瘤研究所 | 具有e3-19k蛋白的内质网滞留结构域内突变的腺病毒及其在癌症治疗中的应用 |
| US20090081639A1 (en) | 2007-05-31 | 2009-03-26 | Phil Hill | Assay for sensitivity to chemotherapeutic agents |
| WO2009065800A1 (en) | 2007-11-20 | 2009-05-28 | Crucell Holland B.V. | Recombinant human adenoviruses for eliciting mucosal immune responses |
| CA2706257C (en) | 2007-11-28 | 2017-06-06 | The Trustees Of The University Of Pennsylvania | Simian subfamily b adenovirus sadv-28, -27, -29, -32, -33 and -35 and uses thereof |
| CN101883858B (zh) | 2007-11-28 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用 |
| EP2220217A2 (en) | 2007-11-28 | 2010-08-25 | The Trustees of the University of Pennsylvania | Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof |
| EP2252316A2 (en) | 2008-02-07 | 2010-11-24 | Andrew Baker | Modulation of adenoviral tropism |
| CN102016011B (zh) | 2008-03-04 | 2013-12-11 | 宾夕法尼亚大学托管会 | 猿猴腺病毒sadv-36、-42.1、-42.2和-44及其应用 |
| WO2009117656A2 (en) | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
| WO2009149252A1 (en) | 2008-06-04 | 2009-12-10 | Cornell University | Vaccines for prevention and treatment of addiction |
| CN102066365A (zh) | 2008-06-19 | 2011-05-18 | 米伦纽姆医药公司 | 噻吩或噻唑衍生物和其作为pi3k抑制剂的用途 |
| KR101034811B1 (ko) | 2008-08-25 | 2011-05-16 | 단국대학교 산학협력단 | 조직 특이적 프로모터와 암 특이 유전자를 타겟팅하는트랜스-스플라이싱 라이보자임을 포함하는 재조합아데노바이러스 및 이의 용도 |
| EP2352516A2 (en) | 2008-09-26 | 2011-08-10 | Auburn University | Immunization of avians by mucosal administration of non-replicating vectored vaccines |
| DK2350269T3 (en) | 2008-10-31 | 2015-12-07 | Univ Pennsylvania | ABE ADENOVIRUS WITH SADV-46 HEXONCAPSIDE PROTEINS AND APPLICATIONS THEREOF |
| US9345787B2 (en) | 2008-12-22 | 2016-05-24 | Targovax Oy | Adenoviral vectors and methods and uses related thereto |
| ES2612889T3 (es) | 2008-12-22 | 2017-05-19 | Targovax Oy | Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos |
| MX2011007980A (es) | 2009-02-02 | 2011-08-17 | Okairos Ag | Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas. |
| PT2403951E (pt) | 2009-03-02 | 2016-01-29 | Univ California | Mutantes de adenovírus e1a e e1b de tumores |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| CA2762203A1 (en) | 2009-05-29 | 2010-12-02 | Soumitra Roy | Simian adenovirus 41 and uses thereof |
| US8865182B2 (en) | 2009-07-31 | 2014-10-21 | Paxvax, Inc. | Adenoviral-based vectors |
| US9555089B2 (en) | 2009-08-18 | 2017-01-31 | The Rockefeller University | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
| WO2011022002A1 (en) | 2009-08-18 | 2011-02-24 | The Rockefeller University | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
| KR101248912B1 (ko) | 2009-12-31 | 2013-03-29 | 한양대학교 산학협력단 | 항혈관신생 활성을 가지는 재조합 아데노바이러스 |
| WO2011101869A1 (en) | 2010-02-22 | 2011-08-25 | Transgene Biotek Ltd. | Adeno-associated virus 2/8 - micro rna-101 therapy for liver cancer |
| CN102191245B (zh) | 2010-03-15 | 2013-11-13 | 浙江东方基因生物制品有限公司 | 应用肿瘤特异性启动子表达报告基因来检测循环血中肿瘤细胞的方法和试剂 |
| CN102892429B (zh) | 2010-03-17 | 2016-08-31 | 康奈尔大学 | 基于被破坏的腺病毒的抗滥用药物疫苗 |
| CN102844329B (zh) | 2010-04-14 | 2016-01-20 | 财团法人牧岩生命工学研究所 | 分离自猿腺病毒血清型19的六邻体、其高变区和使用其的嵌合型腺病毒 |
| WO2011133040A2 (en) | 2010-04-23 | 2011-10-27 | Orca Therapeutics B.V. | Replication-competent adenoviruses |
| KR101497035B1 (ko) | 2010-04-26 | 2015-02-27 | 주식회사 녹십자 | 종양 특이적 프로모터 및 이를 포함하는 종양살상 바이러스 벡터 |
| KR20180122043A (ko) | 2010-06-10 | 2018-11-09 | 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 | 데스모글레인 2(디에스쥐2)와 아데노바이러스의 상호작용을 위한 방법 및 시스템 |
| WO2012003287A2 (en) | 2010-06-30 | 2012-01-05 | The Johns Hopkins University | Compositions and methods for detecting and quantifying circulating tumor cells ctcs |
| BR112013003579A2 (pt) | 2010-08-16 | 2016-06-07 | Salk Inst For Biological Studi | adenovírus, células, e, métodos para tratar câncer |
| EP2606127B1 (en) | 2010-08-16 | 2019-03-20 | Salk Institute For Biological Studies | Adenoviral assembly method |
| WO2012022496A2 (en) | 2010-08-19 | 2012-02-23 | Per Sonne Holm | Method for killing tumor stem cells |
| EP2619312A1 (en) | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| EP2619224A1 (en) | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| EP3075860A1 (en) | 2010-11-23 | 2016-10-05 | The Trustees of the University of Pennsylvania | Subfamily e simian adenovirus a1295 and uses thereof |
| WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
| WO2012088041A1 (en) | 2010-12-20 | 2012-06-28 | Genvec, Inc. | Adenoviral vector-based dengue fever vaccine |
| CN102174479B (zh) | 2011-03-02 | 2013-04-03 | 北京锤特生物科技有限公司 | 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用 |
| JP5975352B2 (ja) | 2011-03-25 | 2016-08-23 | 国立大学法人 鹿児島大学 | 癌幹細胞を標的とするウイルスベクター |
| US20140341857A1 (en) | 2011-05-16 | 2014-11-20 | Institut Gustave Roussy | Combination of oncolytic adenoviruses with histone deacetylase inhibitors |
| WO2012162342A2 (en) | 2011-05-23 | 2012-11-29 | The Wistar Institute Of Anatomy And Biology | Influenza vaccines containing modified adenovirus vectors |
| GB201108879D0 (en) | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| CN102260712B (zh) | 2011-05-31 | 2013-10-02 | 北京锤特生物科技有限公司 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
| JP5971599B2 (ja) | 2011-08-23 | 2016-08-17 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 制限増殖型アデノウイルス |
| WO2013036791A2 (en) | 2011-09-09 | 2013-03-14 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
| JP6757120B2 (ja) | 2011-10-05 | 2020-09-16 | ジェンヴェック エルエルシー | アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法 |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| US9267153B2 (en) | 2011-12-15 | 2016-02-23 | Washington University | Porcine knob xenotype chimeric adenoviral vector for dendritic cell infection |
| SG10201913795TA (en) | 2012-02-02 | 2020-03-30 | Univ Texas | Adenoviruses expressing heterologous tumor-associated antigens |
| CA2864956C (en) | 2012-03-12 | 2021-11-09 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| CA2867129C (en) | 2012-03-13 | 2023-11-21 | Salk Institute For Biological Studies | Selective cell targeting using adenovirus and chemical dimers |
| IN2014DN06898A (enExample) | 2012-03-14 | 2015-05-15 | Salk Inst For Biological Studi | |
| US9017672B2 (en) | 2012-05-11 | 2015-04-28 | Immunicum Aktiebolag | Hexon Tat-PTD modified adenovirus and uses thereof |
| JP6293738B2 (ja) | 2012-05-18 | 2018-03-14 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 亜科ｅサルアデノウイルスａ１３０２、ａ１３２０、ａ１３３１及びａ１３３７ならびにそれらの使用 |
| US9476061B2 (en) | 2012-05-24 | 2016-10-25 | Janssen Vaccines & Prevention B.V. | Adenoviral vectors for transduction of vascular tissue |
| EP2855669B1 (en) | 2012-05-29 | 2018-10-10 | GenVec, Inc. | Modified serotype 28 adenoviral vectors |
| AU2013203696A1 (en) | 2012-06-25 | 2014-01-16 | University Of Canberra | Recombinant Viral Vectors and Uses Therefor |
| AU2013323775B2 (en) | 2012-09-25 | 2018-10-18 | University Of Washington Through Its Center For Commercialization | Desmoglein 2 (DSG2) binding proteins and uses therefor |
| KR101429696B1 (ko) | 2012-11-21 | 2014-08-13 | 국립암센터 | 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도 |
| EP2961417A1 (en) | 2013-02-28 | 2016-01-06 | PsiOxus Therapeutics Limited | A process for the production of adenovirus |
| WO2014160475A1 (en) | 2013-03-13 | 2014-10-02 | Aboody Karen S | Tropic cell based virotherapy for the treatment of cancer |
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| WO2014170389A1 (en) | 2013-04-18 | 2014-10-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| ES2878549T3 (es) | 2013-06-18 | 2021-11-19 | Dnatrix Inc | Adenovirus oncolítico para su uso en el tratamiento del cáncer cerebral |
| JP2016538327A (ja) | 2013-09-24 | 2016-12-08 | ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション | デスモグレイン２（ｄｓｇ２）結合タンパク質およびその使用 |
| CA2931322A1 (en) | 2013-11-22 | 2015-05-28 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| GB201415579D0 (en) | 2014-09-03 | 2014-10-15 | Psioxus Therapeutics Ltd | A process |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| EP2940128A1 (en) | 2014-04-30 | 2015-11-04 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Adenovirus comprising an albumin-binding moiety |
| NZ726112A (en) | 2014-05-19 | 2021-07-30 | Valo Therapeutics Oy | Coated adenoviruses for immunotherapy |
| KR102365331B1 (ko) | 2014-05-28 | 2022-02-22 | 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 | Reic 유전자를 발현하는 제한 증식형 아데노바이러스 |
| DK3198009T3 (da) | 2014-09-24 | 2021-11-22 | Salk Inst For Biological Studi | Onkolytiske tumorvira og anvendelsesfremgangsmåder |
| WO2016106178A1 (en) | 2014-12-24 | 2016-06-30 | The Uab Research Foundation, Inc. | Multitargeting onocolytic adenovirus, methods of use, and methods of making |
| EP3247807B1 (en) | 2015-01-20 | 2020-12-16 | Adcure Biotechnologies, LLC. | Detargeted adenovirus variants and related methods |
| WO2016141073A1 (en) | 2015-03-02 | 2016-09-09 | Washington University | Induction of pacemaker-like cells from cardiomyocytes |
| CN107406859A (zh) | 2015-03-17 | 2017-11-28 | 倾斜生物医疗公司 | 编码双特异性抗体的溶瘤腺病毒及与其相关的方法和用途 |
| EP3072900A1 (en) | 2015-03-27 | 2016-09-28 | Medizinische Hochschule Hannover | Anti-tumour medicament based on adenovirus |
| GB201505860D0 (en) | 2015-04-07 | 2015-05-20 | Agalimmune Ltd | Therapeutic compositions and methods of use for treating cancer |
| GB201513176D0 (en) | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| US20180369417A1 (en) | 2015-09-01 | 2018-12-27 | Industry-University Coorperation Foundation Hanyang University | Antitumor immunity enhancing composition containing adenovirus simultaneously expressing il-12 and shvegf |
| ES2837400T3 (es) | 2015-10-05 | 2021-06-30 | Salk Inst For Biological Studi | Adenovirus sintético con tropismo para los tejidos dañados para su uso en la promoción de la reparación de heridas y regeneración tisular |
| ES2994611T3 (en) | 2015-10-19 | 2025-01-27 | Cg Oncology Inc | Methods of treating solid or lymphatic tumors by combination therapy |
| WO2017075395A1 (en) | 2015-10-28 | 2017-05-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Tumor-specific adenovirus vectors and therapeutic uses |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| WO2017156349A1 (en) | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
| US20170314044A1 (en) | 2016-05-02 | 2017-11-02 | Regents Of The University Of Minnesota | Adenovirus constructs and methods |
| US20190201551A1 (en) | 2016-05-23 | 2019-07-04 | Washington University | Pulmonary targeted cas9/crispr for in vivo editing of disease genes |
| WO2017205875A1 (en) | 2016-05-27 | 2017-11-30 | Dnatrix, Inc. | Adenovirus and immunomodulator combination therapy |
| GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
| US11155832B2 (en) | 2016-09-30 | 2021-10-26 | Genvec, Inc. | Adenovectors for delivery of therapeutic genetic material into T cells |
| FI20165814A (fi) | 2016-10-27 | 2018-04-28 | Tilt Biotherapeutics Oy | Interleukiini 8 (il-8) prognostisena ja ennustavana biomarkkerina ja koostumukset ja vektorit käytettäväksi onkolyyttisessa immunoterapiassa |
| WO2018085461A1 (en) | 2016-11-01 | 2018-05-11 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
| WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083259A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| EP3512533B9 (en) | 2016-11-17 | 2021-05-19 | VCN Biosciences SL | Oncolytic viral vectors for use in the treatment of retinoblastoma |
| ES2959811T3 (es) | 2016-12-09 | 2024-02-28 | Glaxosmithkline Biologicals Sa | Construcciones de adenovirus de chimpancé con antígenos de Lyssavirus |
| GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| US10232053B2 (en) | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
| WO2018125970A1 (en) | 2016-12-30 | 2018-07-05 | Salk Institute For Biological Studies | Synthetic adenoviruses targeting bone tissue and uses thereof |
| SG11201906973TA (en) | 2017-01-30 | 2019-08-27 | Epicentrx Inc | Multiple transgene recombinant adenovirus |
| US20190352669A1 (en) | 2017-01-30 | 2019-11-21 | Epicentrx, Inc. | Tumor selective tata-box and caat-box mutants |
| EP3610003A4 (en) | 2017-04-10 | 2021-01-06 | EpicentRx, Inc. | RECOMBINANT VIRUS PRODUCTION PROCESS |
| EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| CA3060573A1 (en) | 2017-04-21 | 2018-10-25 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| WO2018201017A1 (en) | 2017-04-27 | 2018-11-01 | Washington University | Dendritic cell targeted adenovirus for vaccination |
| WO2018204677A1 (en) | 2017-05-04 | 2018-11-08 | Epicentrx, Inc. | Oncolytic adenovirus formulation |
| EP3630959A4 (en) | 2017-05-24 | 2021-03-17 | EpicentRx, Inc. | ANTI-ANGIOGENIC ADENOVIRUS |
| EP3641814A4 (en) | 2017-06-19 | 2021-06-23 | Medicenna Therapeutics Inc. | USES AND METHODS FOR IL-2 SUPERAGONISTS AND AGONISTS AND FUSIONS THEREOF |
| WO2019016756A1 (en) | 2017-07-21 | 2019-01-24 | Glaxosmithkline Biologicals Sa | ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES |
| SI3460052T1 (sl) | 2017-09-20 | 2020-03-31 | Immunicum Ab | Izboljšane alogene dendritične celice za uporabo pri zdravljenju raka |
| WO2019073059A1 (en) | 2017-10-12 | 2019-04-18 | Freeline Therapeutics Limited | ADENOVIRAL AUXILIARY VIRUSES WITH DEFECTIVE CYCLE LIFE, PRODUCTION AND USE FOR THE PRODUCTION OF RAAV |
| US11236361B2 (en) | 2017-10-31 | 2022-02-01 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| AU2018359492B2 (en) | 2017-10-31 | 2023-12-14 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| EP3704256A1 (en) | 2017-10-31 | 2020-09-09 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
| MX2020004487A (es) | 2017-10-31 | 2020-08-13 | Janssen Vaccines & Prevention Bv | Adenovirus y usos de estos. |
| GB201802539D0 (en) | 2018-02-16 | 2018-04-04 | Univ College Cardiff Consultants Ltd | Modified adenoviruses |
| GB201804468D0 (en) | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
| GB201804473D0 (en) | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | Modified oncolytic adenoviruses |
| EP3773649A4 (en) | 2018-03-28 | 2022-02-23 | EpicentRx, Inc. | PERSONALIZED CANCER VACCINE |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| WO2019202118A1 (en) | 2018-04-20 | 2019-10-24 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| CN112638936A (zh) | 2018-06-12 | 2021-04-09 | 葛兰素史密丝克莱恩生物有限公司 | 腺病毒多核苷酸和多肽 |
| WO2020014539A1 (en) | 2018-07-11 | 2020-01-16 | Epicentrx, Inc. | Methods and compositions for targeting cancer cells for treatment |
| WO2020046130A1 (en) | 2018-08-31 | 2020-03-05 | Orca Therapeutics B.V. | Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (gsk3) and methods of killing aberrant cells |
| JP7384457B2 (ja) | 2018-10-09 | 2023-11-21 | ナイキジェン，リミテッド | ウイルスベクターを調製するための組成物および方法 |
-
2014
- 2014-03-14 CA CA2903582A patent/CA2903582C/en active Active
- 2014-03-14 SG SG11201507393TA patent/SG11201507393TA/en unknown
- 2014-03-14 CA CA3115891A patent/CA3115891A1/en not_active Abandoned
- 2014-03-14 EP EP14770520.6A patent/EP2971008B1/en active Active
- 2014-03-14 WO PCT/US2014/029587 patent/WO2014153204A1/en not_active Ceased
- 2014-03-14 KR KR1020157028296A patent/KR102089121B1/ko active Active
- 2014-03-14 JP JP2016503154A patent/JP6576326B2/ja active Active
- 2014-03-14 AU AU2014236207A patent/AU2014236207B2/en active Active
-
2015
- 2015-09-14 US US14/852,981 patent/US11077156B2/en active Active
-
2021
- 2021-07-09 US US17/371,546 patent/US20220096577A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6576326B2 (ja) | 2019-09-18 |
| US11077156B2 (en) | 2021-08-03 |
| EP2971008B1 (en) | 2018-07-25 |
| KR20150130441A (ko) | 2015-11-23 |
| US20220096577A1 (en) | 2022-03-31 |
| SG11201507393TA (en) | 2015-10-29 |
| CA2903582A1 (en) | 2014-09-25 |
| CA3115891A1 (en) | 2014-09-25 |
| AU2014236207B2 (en) | 2019-05-23 |
| AU2014236207A1 (en) | 2015-09-17 |
| KR102089121B1 (ko) | 2020-03-13 |
| EP2971008A4 (en) | 2016-09-14 |
| EP2971008A1 (en) | 2016-01-20 |
| US20150374766A1 (en) | 2015-12-31 |
| WO2014153204A1 (en) | 2014-09-25 |
| JP2016516407A (ja) | 2016-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220096577A1 (en) | Oncolytic adenovirus compositions | |
| US20240342231A1 (en) | Selective cell targeting using adenovirus and chemical dimers | |
| AU2011292119B2 (en) | Anti-cancer adenoviruses | |
| US20110053249A1 (en) | Adenoviruses Mutated In The VA Genes For Cancer Treatment | |
| CN102108356B (zh) | 新颖启动子及包含其之病毒载体 | |
| TWI391486B (zh) | 新穎啟動子及包含其之病毒載體 | |
| ZA200406798B (en) | Use of adenoviruses in the va genes for cancer treatment | |
| HK1080112A (en) | Use of adenoviruses mutated in the va genes for cancer treatment | |
| HK1071060B (en) | Use of adenoviruses mutated in the va genes for cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190218 |